Homocysteine levels after acute levodopa intake in patients with Parkinson's disease
Identifieur interne : 002273 ( Main/Exploration ); précédent : 002272; suivant : 002274Homocysteine levels after acute levodopa intake in patients with Parkinson's disease
Auteurs : Thomas Müller [Allemagne] ; Wilfried Kuhn [Allemagne]Source :
- Movement Disorders [ 0885-3185 ] ; 2009-07-15.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Aged, Analysis of Variance, Antiparkinson Agents (administration & dosage), Antiparkinson Agents (blood), Dihydroxyphenylalanine (analogs & derivatives), Dihydroxyphenylalanine (blood), Female, Homocystein, Homocysteine (blood), Human, Humans, Levodopa, Levodopa (administration & dosage), Levodopa (blood), Male, Middle Aged, Nervous system diseases, Parkinson Disease (blood), Parkinson Disease (drug therapy), Parkinson disease, Parkinson's disease, Severity of Illness Index, Statistics as Topic, Time Factors, absorption, homocysteine, levodopa.
- MESH :
- chemical , administration & dosage : Antiparkinson Agents, Levodopa.
- chemical , analogs & derivatives : Dihydroxyphenylalanine.
- chemical , blood : Antiparkinson Agents, Dihydroxyphenylalanine, Homocysteine, Levodopa.
- blood : Parkinson Disease.
- drug therapy : Parkinson Disease.
- Aged, Analysis of Variance, Female, Humans, Male, Middle Aged, Severity of Illness Index, Statistics as Topic, Time Factors.
Abstract
Levodopa (L‐dopa) administered with a dopadecarboxylase inhibitor (DDI) increases homocysteine plasma levels. This may support the onset of atherosclerosis‐related disorders and neuropsychiatric complications in patients with Parkinson's disease (PD). This homocysteine elevation is considered as long‐term effect of chronic L‐dopa/DDI treatment. Little is known about the acute effects of L‐dopa/DDI intake on homocysteine generation. The objective of this trial was to investigate the relations between L‐dopa and homocysteine after acute L‐dopa/DDI administration in PD patients with different L‐dopa metabolism. Thirty PD patients were divided into groups with superior (I) and less (II) L‐dopa absorption after standardized intake of 125 mg L‐dopa/benserazide with determination of L‐dopa, 3‐O‐methyl‐dopa (3‐OMD) and homocysteine in plasma at baseline, 30, 60, and 90 minutes. There was a homocysteine increase in Group I (F = 5; P = 0.005) and a moderate decrease in Group II (F = 4.27; P = 0.01). A rise of 3‐OMD (F = 10.51; P < 0.0001) appeared in Group I, but not in Group II (F = 0.91; P = 0.44), accordingly L‐dopa accumulation was better in Group I than in Group II. Thus, in conclusion, L‐dopa metabolism is an important component for homocysteine elevation after one time L‐dopa/DDI administration in PD patients. © 2009 Movement Disorder Society
Url:
DOI: 10.1002/mds.22607
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002041
- to stream Istex, to step Curation: 002041
- to stream Istex, to step Checkpoint: 000E75
- to stream PubMed, to step Corpus: 001D07
- to stream PubMed, to step Curation: 001D07
- to stream PubMed, to step Checkpoint: 001D78
- to stream Ncbi, to step Merge: 002670
- to stream Ncbi, to step Curation: 002670
- to stream Ncbi, to step Checkpoint: 002670
- to stream Main, to step Merge: 002B34
- to stream PascalFrancis, to step Corpus: 000E31
- to stream PascalFrancis, to step Curation: 001E88
- to stream PascalFrancis, to step Checkpoint: 000E52
- to stream Main, to step Merge: 002F49
- to stream Main, to step Curation: 002273
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Homocysteine levels after acute levodopa intake in patients with Parkinson's disease</title><author><name sortKey="Muller, Thomas" sort="Muller, Thomas" uniqKey="Muller T" first="Thomas" last="Müller">Thomas Müller</name></author><author><name sortKey="Kuhn, Wilfried" sort="Kuhn, Wilfried" uniqKey="Kuhn W" first="Wilfried" last="Kuhn">Wilfried Kuhn</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:D1FB1EF54B50C9452FCEDC8885BBAEE5DE0A7E2C</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1002/mds.22607</idno><idno type="url">https://api.istex.fr/document/D1FB1EF54B50C9452FCEDC8885BBAEE5DE0A7E2C/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002041</idno><idno type="wicri:Area/Istex/Curation">002041</idno><idno type="wicri:Area/Istex/Checkpoint">000E75</idno><idno type="wicri:doubleKey">0885-3185:2009:Muller T:homocysteine:levels:after</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:19425084</idno><idno type="wicri:Area/PubMed/Corpus">001D07</idno><idno type="wicri:Area/PubMed/Curation">001D07</idno><idno type="wicri:Area/PubMed/Checkpoint">001D78</idno><idno type="wicri:Area/Ncbi/Merge">002670</idno><idno type="wicri:Area/Ncbi/Curation">002670</idno><idno type="wicri:Area/Ncbi/Checkpoint">002670</idno><idno type="wicri:Area/Main/Merge">002B34</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:09-0349936</idno><idno type="wicri:Area/PascalFrancis/Corpus">000E31</idno><idno type="wicri:Area/PascalFrancis/Curation">001E88</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000E52</idno><idno type="wicri:doubleKey">0885-3185:2009:Muller T:homocysteine:levels:after</idno><idno type="wicri:Area/Main/Merge">002F49</idno><idno type="wicri:Area/Main/Curation">002273</idno><idno type="wicri:Area/Main/Exploration">002273</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Homocysteine levels after acute levodopa intake in patients with Parkinson's disease</title><author><name sortKey="Muller, Thomas" sort="Muller, Thomas" uniqKey="Muller T" first="Thomas" last="Müller">Thomas Müller</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Neurology, St. Joseph Hospital Berlin‐Weissensee, Gartenstrasse 1, Berlin</wicri:regionArea><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Neurology, St. Josef Hospital, Ruhr University Bochum, Gudrunstrasse 56, Bochum</wicri:regionArea><wicri:noRegion>Bochum</wicri:noRegion><wicri:noRegion>Bochum</wicri:noRegion></affiliation></author><author><name sortKey="Kuhn, Wilfried" sort="Kuhn, Wilfried" uniqKey="Kuhn W" first="Wilfried" last="Kuhn">Wilfried Kuhn</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Neurology, St. Josef Hospital, Ruhr University Bochum, Gudrunstrasse 56, Bochum</wicri:regionArea><wicri:noRegion>Bochum</wicri:noRegion><wicri:noRegion>Bochum</wicri:noRegion></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Neurology, Leopoldina Hospital, Gustav Adolfstrasse 8, Schweinfurt</wicri:regionArea><wicri:noRegion>Schweinfurt</wicri:noRegion><wicri:noRegion>Schweinfurt</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2009-07-15">2009-07-15</date><biblScope unit="vol">24</biblScope><biblScope unit="issue">9</biblScope><biblScope unit="page" from="1339">1339</biblScope><biblScope unit="page" to="1343">1343</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">D1FB1EF54B50C9452FCEDC8885BBAEE5DE0A7E2C</idno><idno type="DOI">10.1002/mds.22607</idno><idno type="ArticleID">MDS22607</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Analysis of Variance</term><term>Antiparkinson Agents (administration & dosage)</term><term>Antiparkinson Agents (blood)</term><term>Dihydroxyphenylalanine (analogs & derivatives)</term><term>Dihydroxyphenylalanine (blood)</term><term>Female</term><term>Homocystein</term><term>Homocysteine (blood)</term><term>Human</term><term>Humans</term><term>Levodopa</term><term>Levodopa (administration & dosage)</term><term>Levodopa (blood)</term><term>Male</term><term>Middle Aged</term><term>Nervous system diseases</term><term>Parkinson Disease (blood)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson disease</term><term>Parkinson's disease</term><term>Severity of Illness Index</term><term>Statistics as Topic</term><term>Time Factors</term><term>absorption</term><term>homocysteine</term><term>levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Dihydroxyphenylalanine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antiparkinson Agents</term><term>Dihydroxyphenylalanine</term><term>Homocysteine</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Analysis of Variance</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Severity of Illness Index</term><term>Statistics as Topic</term><term>Time Factors</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Homme</term><term>Homocystéine</term><term>Lévodopa</term><term>Maladie de Parkinson</term><term>Pathologie du système nerveux</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Levodopa (L‐dopa) administered with a dopadecarboxylase inhibitor (DDI) increases homocysteine plasma levels. This may support the onset of atherosclerosis‐related disorders and neuropsychiatric complications in patients with Parkinson's disease (PD). This homocysteine elevation is considered as long‐term effect of chronic L‐dopa/DDI treatment. Little is known about the acute effects of L‐dopa/DDI intake on homocysteine generation. The objective of this trial was to investigate the relations between L‐dopa and homocysteine after acute L‐dopa/DDI administration in PD patients with different L‐dopa metabolism. Thirty PD patients were divided into groups with superior (I) and less (II) L‐dopa absorption after standardized intake of 125 mg L‐dopa/benserazide with determination of L‐dopa, 3‐O‐methyl‐dopa (3‐OMD) and homocysteine in plasma at baseline, 30, 60, and 90 minutes. There was a homocysteine increase in Group I (F = 5; P = 0.005) and a moderate decrease in Group II (F = 4.27; P = 0.01). A rise of 3‐OMD (F = 10.51; P < 0.0001) appeared in Group I, but not in Group II (F = 0.91; P = 0.44), accordingly L‐dopa accumulation was better in Group I than in Group II. Thus, in conclusion, L‐dopa metabolism is an important component for homocysteine elevation after one time L‐dopa/DDI administration in PD patients. © 2009 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Allemagne</li></country><region><li>Berlin</li></region><settlement><li>Berlin</li></settlement></list><tree><country name="Allemagne"><region name="Berlin"><name sortKey="Muller, Thomas" sort="Muller, Thomas" uniqKey="Muller T" first="Thomas" last="Müller">Thomas Müller</name></region><name sortKey="Kuhn, Wilfried" sort="Kuhn, Wilfried" uniqKey="Kuhn W" first="Wilfried" last="Kuhn">Wilfried Kuhn</name><name sortKey="Kuhn, Wilfried" sort="Kuhn, Wilfried" uniqKey="Kuhn W" first="Wilfried" last="Kuhn">Wilfried Kuhn</name><name sortKey="Muller, Thomas" sort="Muller, Thomas" uniqKey="Muller T" first="Thomas" last="Müller">Thomas Müller</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002273 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002273 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:D1FB1EF54B50C9452FCEDC8885BBAEE5DE0A7E2C
|texte= Homocysteine levels after acute levodopa intake in patients with Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |